Sanofi Consumer Healthcare India Ltd
- Market Cap ₹ 10,947 Cr.
- Current Price ₹ 4,764
- High / Low ₹ 5,954 / 3,950
- Stock P/E 43.3
- Book Value ₹ 167
- Dividend Yield 1.15 %
- ROCE 108 %
- ROE 86.2 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Company is expected to give good quarter
- Company has a good return on equity (ROE) track record: 3 Years ROE 83.6%
Cons
- Stock is trading at 28.6 times its book value
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE Healthcare BSE 1000
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Dec 2023 8m | Dec 2024 | Mar 2025 | Dec 2025 | TTM | |
|---|---|---|---|---|---|
| 555 | 724 | 878 | 878 | 935 | |
| 337 | 454 | 569 | 569 | 601 | |
| Operating Profit | 219 | 271 | 309 | 309 | 334 |
| OPM % | 39% | 37% | 35% | 35% | 36% |
| 2 | -15 | 25 | 25 | 25 | |
| Interest | 0 | 4 | 2 | 2 | 2 |
| Depreciation | 2 | 4 | 12 | 12 | 13 |
| Profit before tax | 219 | 247 | 320 | 320 | 344 |
| Tax % | 25% | 27% | 25% | 25% | |
| 165 | 181 | 240 | 240 | 258 | |
| EPS in Rs | 78.59 | 104.25 | 104.25 | 111.98 | |
| Dividend Payout % | 6% | 70% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 38% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 35% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -4% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 84% |
| Last Year: | 86% |
Balance Sheet
Figures in Rs. Crores
| Dec 2023 | Dec 2024 | Jun 2025 | |
|---|---|---|---|
| Equity Capital | 2 | 23 | 23 |
| Reserves | 206 | 250 | 234 |
| 0 | 20 | 28 | |
| 138 | 138 | 137 | |
| Total Liabilities | 345 | 431 | 422 |
| 5 | 29 | 42 | |
| CWIP | 3 | 1 | 0 |
| Investments | 0 | 0 | 0 |
| 338 | 402 | 380 | |
| Total Assets | 345 | 431 | 422 |
Cash Flows
Figures in Rs. Crores
| Dec 2023 | Dec 2024 | Mar 2025 | Dec 2025 | |
|---|---|---|---|---|
| -0 | 439 | |||
| 0 | 2 | |||
| 2 | -116 | |||
| Net Cash Flow | 2 | 325 | ||
| Free Cash Flow | -4 | 429 | ||
| CFO/OP | 2% | 208% |
Ratios
Figures in Rs. Crores
| Dec 2023 | Dec 2024 | Mar 2025 | Dec 2025 | |
|---|---|---|---|---|
| Debtor Days | 21 | 7 | ||
| Inventory Days | 232 | 80 | ||
| Days Payable | 144 | 138 | ||
| Cash Conversion Cycle | 109 | -51 | ||
| Working Capital Days | 134 | -33 | ||
| ROCE % | 111% |
Insights
In beta| Dec 2023 | Dec 2024 | |
|---|---|---|
| Allegra Market Share (Allergy Category) % |
|
|
| Avil Market Share (Allergy Category) % |
||
| City Reach Number of Cities |
||
| Combiflam Annual Sales Volume Million Tablets |
||
| Combiflam Market Share (Pain Category) % |
||
| Combiflam Sales Velocity Strips per minute |
||
| DePURA Market Share (Vitamin D Category) % |
||
| Total Employees Number |
||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Resignation of Statutory Auditors
1h - Kalyaniwalla & Mistry LLP resigned as Sanofi Consumer Healthcare India’s statutory auditor effective 30 April 2026 over fee dispute.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
6h - Copy of Newspaper Publication of Unaudited Financial Result for the quarter ended 31st March 2026 is enclosed.
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
6h - Sanofi Consumer Healthcare India reported Q1’26 revenue of ₹2,292 million and PAT of ₹678 million, up 33% and 36%.
-
Results - Financial Results For March 31, 2026
2d - Q4 FY26 unaudited results approved on 28 Apr 2026; revenue 2,292 million, profit 678 million.
-
Board Meeting Outcome for Outcome Of Board Meeting Held On Tuesday, 28Th April 2026
2d - Q4 FY26 unaudited results: revenue Rs 2,292 crore, profit Rs 678 crore; board approved on 28 Apr 2026.
Annual reports
Concalls
-
Mar 2026Transcript PPT
Business Overview:[1][2]
SCHIL was formed following its demerger from Sanofi India Limited, to establish a standalone Consumer Healthcare (CHC) business. It operates in the Consumer Healthcare (CHC) sector, providing self-care solutions across various health categories including allergy relief, pain management, and wellness